Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve
advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has …

PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand …

One of the great challenges in therapeutic oncology is determining who might achieve
survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA …

Simple Summary Treatment strategies in advanced, metastatic small cell lung cancer have
been recently implemented by the combination of chemotherapy and immunotherapy …

Background VEGF promotes an immunosuppressive microenvironment and contributes to
immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the …

Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …

Classical mathematical models of tumor growth have shaped our understanding of cancer
and have broad practical implications for treatment scheduling and dosage. However, even …

Individual participant data (IPD) from oncology clinical trials is invaluable for identifying
factors that influence trial success and failure, improving trial design and interpretation, and …

Liver cancer is the third most common cause of cancer-related mortality worldwide, with over
780,000 deaths in 2018. About 90% of liver cancer cases are hepatocellular carcinoma …

Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte–associated antigen 4
(CTLA-4) and programmed death 1 (PD-1) proteins transformed the management of …